ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the sale, the director now owns 210,346 shares in the company, valued at $2,589,359.26. This represents a 19.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Laura Shawver also recently made the following trade(s):

• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $11.10, for a total value of $555,000.00.
• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock opened at $12.80 on Friday. The stock has a market capitalization of $1.24 billion, a P/E ratio of -25.10 and a beta of 0.99. The business’s 50 day simple moving average is $12.37 and its two-hundred day simple moving average is $13.13. ARS Pharmaceuticals, Inc. has a one year low of $6.29 and a one year high of $18.51.

Analyst Ratings Changes

A number of research analysts have weighed in on SPRY shares. Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Raymond James boosted their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $26.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SPRY. Renaissance Technologies LLC lifted its position in shares of ARS Pharmaceuticals by 884.9% in the second quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock worth $1,056,000 after buying an additional 111,500 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter worth approximately $180,000. Creative Planning boosted its stake in shares of ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after purchasing an additional 2,307 shares during the period. nVerses Capital LLC purchased a new position in shares of ARS Pharmaceuticals during the third quarter worth approximately $30,000. Finally, Raymond James & Associates purchased a new position in ARS Pharmaceuticals during the 3rd quarter worth $2,969,000. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.